Surufatinib clinical trials
Also written HMPL-012 and Sulfatinib.
How each study uses surufatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the surufatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
82 studies that test it; most in 2021 (17)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 17 |
| 2022 | 15 |
| 2023 | 14 |
| 2024 | 11 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 62
Hutchison Medipharma Limited (15) · Sun Yat-sen University (9) · Fudan University (6) · Fujian Cancer Hospital (6) · Tianjin Medical University Cancer Institute and Hospital (4) · Hutchmed (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Wuhan Union Hospital, China (3)
Often tested with
Tested in the same studies.
Toripalimab (11) · Sintilimab (9) · Tislelizumab (5) · Gemcitabine (5) · Albumin-Bound Paclitaxel (4) · Paclitaxel (4) · Serplulimab (3) · Pamiparib (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test surufatinib.
- Dec 2026Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaPhase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Dec 2026A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Phase 2 · Fujian Cancer Hospital
- Dec 2026A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaPhase 1/2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Dec 2026A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerPhase 2 · Fudan University
- Aug 2027Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationPhase 2 · RenJi Hospital
- Sep 2027Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine TumorsPhase 2 · Shanghai Chest Hospital
- Sep 2027An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine TumorsPhase 1/2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Nov 2027Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsPhase 4 · Shanghai Zhongshan Hospital
Studies
Open first, then newest update. How each study uses surufatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 82
- Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal CancerRecruitingPhase 2/3The First Hospital of Jilin UniversityNCT07935759Written as Surufatinib 250mg/d qd once dailyHow we know
- An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine TumorsRecruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06038461Written as Surufatinib Combined With Temozolomide and S-1How we know
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingPhase 1/2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT05747729Written as Surufatinib and SerplulimabHow we know
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT07436741Written as surufatinib + gemcitabine + nab-paclitaxelHow we know
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07469956Written as SurufatinibHow we know
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung CancerRecruitingPhase 2Sun Yat-sen UniversityNCT06719700Written as Consolidation Therapy with Toripalimab and SurufatinibHow we know
- Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine TumorsRecruitingPhase 2Shanghai Chest HospitalNCT07357623Written as Surufatinib Combined With Standard chemotherapyHow we know
- Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsRecruitingPhase 4Shanghai Zhongshan HospitalNCT07272512Written as SurufatinibHow we know
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT05472948Written as SurufatinibHow we know
- Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging SystemNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07279532Written as surufatinibHow we know
- Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07156019Written as Sintilimab+Temozolomide+SurufatinibHow we know
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT05969171Written as Surufatinib, gemcitabine, nab-paclitaxelHow we know
- Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07086456Written as SurufatinibHow we know
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingPhase 1/2Chinese PLA General HospitalNCT05218889Written as surufatinib + camrelizumab + nab-paclitaxel + S-1How we know
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingPhase 2Fujian Cancer HospitalNCT06654947Written as Surufatinib+Toripalimab+GEMOXHow we know
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingPhase 2Dai, GuanghaiNCT06708858Written as SurufatinibHow we know
- Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06656559Written as Envafolimab and SurufatinibHow we know
- Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingPhase 2RenJi HospitalNCT06531291Written as SurufatinibHow we know
- Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingPhase 2National Cancer Center, ChinaNCT06414915Written as SurufatinibHow we know
- A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRADNot yet recruitingPhase 2Rui-hua Xu, MD, PhDNCT06329947Written as Surufatinib 250mg/d qd once dailyHow we know
See all 82 studies that test surufatinib →
Given beside what is tested · 5 — surufatinib is usual care or a partner of the new treatment
- Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingPhase 2Sun Yat-sen UniversityNCT07609121Written as SurufatinibHow we know
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingPhase 2Peking UniversityNCT05165407Written as SurufatinibHow we know
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingPhase 1/2Shanghai Zhongshan HospitalNCT05832892Written as surufatinibHow we know
- Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedPhase 2Hutchison Medipharma LimitedNCT05509699Written as SurufatinibHow we know
- Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic CancerCompletedPhase 2Sun Yat-sen UniversityNCT05481463Written as SurufatinibHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call surufatinib · ClinicalTrials.gg INT001634
- MeSH (NLM) C000717729surufatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) B2K5L1L8S9SURUFATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q126122215surufatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116066SurufatinibOne source FDA
- DrugBank DB15106One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717729 | surufatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | B2K5L1L8S9 | SURUFATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q126122215 | surufatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116066 | Surufatinib | One source FDA |
| DrugBank | DB15106 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.